


Robert Birdsall, Brooke Koshe, Scott Berger, Ying Qing Yu, and Weibin Chen  
Waters Corporation Milford, MA

## INTRODUCTION

Polyoxyethylene sorbitan-based nonionic surfactants such as PS-80 (Figure 1) are commonly used in formulated biopharmaceuticals to reduce protein denaturing, aggregation, and adsorption to surfaces. Degradation of surfactants in formulated drugs can decrease overall product efficacy and safety, thus requiring methods to demonstrate drug products are safe and efficacious. Assessment has become increasingly critical with the recent discovery linking trace residual esterases with polysorbate degradation in formulated drug products.

As manufacturing processes are modernized as part of a pharmaceutical quality system (ICH Q10), legacy methods such as HPLC-based separations using wide-bore columns often lack the sensitivity and efficiency needed by today's standards when considering factors such as post-column dispersion and long run-times and their impact on assay performance. Efficient methods that are robust and can incorporate technology that offer improved sensitivity and throughput would be beneficial in ensuring drug product and safety over the products lifecycle.



**Figure 1.** Polyoxyethylene sorbitan monooleate. PS-80 contains a polar head-group and a hydrophobic tail where the head group is comprised of approximately 20 polyoxyethylene (POE) groups.

## METHODS

### LC Conditions:

LC System: ACQUITY UPLC® H-Class Bio System  
Detectors: ACQUITY UPLC® TUV w/5-mm Titanium flow cell  
Absorption Wavelength: 200 nm  
Column: ACQUITY UPLC Protein BEH C4 Column, 300Å, 1.7 µm, 2.1 mm X 100 mm p/n 186004496)  
Column Temperature: 30 °C  
Vials: TruView LCMS certified 12x32mm (p/n 186005669CV)  
Sample Temperature: 10 °C  
Injection Volume: 1 µL

### Mobile phase:


A: H<sub>2</sub>O, 0.1% FA  
B: MeCN, 0.1% FA

### Isocratic conditions:


Flow: 0.200 mL/min

		Recovery		Formulated Sample		
		control	experimental	control	Esterified FA experimental	Free FA experimental
Reagent	Conc.	Volume (µL)	Volume (µL)	Volume (µL)	Volume (µL)	Volume (µL)
IS	0.3% in MeCN	10	10	10	10	10
sample	~	15	15	0	20	20
MeCN	neat	275	0	290	0	0
H <sub>2</sub> O	neat	0	15	0	5	35
NaOH	0.5M	0	30	0	30	0
Incubate	~	1 hr	1 hr	1 hr	1 hr	0 hr
HCl	1.0M	0	15	0	15	0
NaCl	saturate d	0	50	0	50	50
H <sub>2</sub> O	neat	0	0	0	0	15
LLE (top layer)	~	no	yes	no	yes	yes
MeCN	neat	0	75	0	90	90
MeCN	neat	0	100	0	100	100
MeCN	neat	0	100	0	100	100
Final volume after LLE		300	300	300	300	300

## RESULTS AND DISCUSSION




**Figure 2.** Dynamic range and internal standard evaluation. A) A serial dilution series of an oleic acid standard using concentrations ranging from 1000 ppm (0.1%) to 0.24 ppm (0.000024%) was performed using a 5-min isocratic method (65%B) on a UPLC platform. B) Cis-10 nonadecenoic acid was identified as a suitable internal standard that is baseline resolved from oleic acid with no observable carry-over. The high throughput separation showed minimal dispersion and a high degree of linearity demonstrating UPLC platforms are well suited for UV-based assays that are efficient and sensitive in the detection of oleic acid degradation species.




**Figure 3.** Liquid-liquid extraction evaluation. A) Two sets of oleic acid samples representing experimental and control were prepared to assess recovery efficiency of a low-volume liquid-liquid extraction technique. Using the isocratic method in Figure 2, corrected peak area for the oleic acid was determined using the average response of the IS in the control sample. B) The high degree of linearity and agreement between both data sets over the dynamic range of the assay (slope ratio = 1.03) demonstrate oleic acid and a corresponding IS can be extracted over a broad working range with conditions that are compatible with direct injection of samples for efficient and accurate analysis of fatty acids.

### FREE OLEIC ACID RESULTS



### HYDROLYZED mAb RESULTS



Infliximab (PS-80 containing) Trastuzumab (PS-20 containing) Infliximab (PS-80 containing) Trastuzumab (PS-20 containing)

**Figure 4.** Assay applicability and specificity. Free oleic acid was not detected in UV and MS chromatograms of representative samples using the proposed LLE technique. Esterified oleic acid was observed to be present in the infliximab sample in the form of PS-80 at less than 1% relative to the IS (99.08%) peak when the samples underwent base hydrolysis. The absence of an oleic acid peak in the hydrolyzed trastuzumab sample highlights the specificity of the assay and confirms that the infliximab sample showed no detectable signs of degradation in the free oleic acid test demonstrating the assays applicability in the detection of PS-80 degradants in formulated samples.

Method	oleic acid conc. (ppm)	PS-80 (mg)	PS-80 conc. (vol %)	PS-80 conc. (mg/mL)	RSD (%)
multi-point calibration (using Figure 2A data)	12.91	0.00119	0.0051	0.059	4.40
single-point calibration (using Figure 2B data)	13.95	0.00129	0.0055	0.065	4.07

**Table 1.** Quantitation Comparison. Using the oleic acid concentration, a single-point calibration method offered an efficient means to extrapolate PS-80 concentration in a high throughput manner when compared to a more resource dependent multi-point method.

## CONCLUSION

- A robust method in the analysis of PS-80 degradants
- A deployable UV-based workflow in regulated environments
- Minimal sample preparation for improved productivity
- Ability to perform high throughput analysis